Skip to main content
. 2022 Aug 8;10(10):2667–2676.e10. doi: 10.1016/j.jaip.2022.07.027

Table E4.

Participant of immediate hypersensitivity reaction (IHSR) groups in sensitivity analysis

Demographic characteristic IHSR-2
IHSR-3
Cases (N = 284) Controls (N = 1136) P value Cases (N = 188) Controls (N = 752) P value
Age (y)
 >65 103 (36.3) 441 (38.8) .853 74 (39.4) 324 (43.1) .610
 51-65 63 (22.2) 237 (20.9) 42 (22.3) 147 (19.5)
 36-50 62 (21.8) 249 (21.9) 36 (19.1) 156 (20.7)
 ≤35 56 (19.7) 209 (18.4) 36 (19.1) 125 (16.6)
Sex
 Male 61 (21.5) 651 (57.3) <.001 44 (23.4) 446 (59.3) <.001
 Female 223 (78.5) 485 (42.7) 144 (76.6) 306 (40.7)
Comorbidities
 Hypertension 40 (14.1) 148 (13.0) .626 33 (17.6) 120 (16) .582
 Diabetes 12 (4.2) 58 (5.1) .646 8 (11.7) 42 (5.9) .587
 Dyslipidemia 16 (5.6) 54 (4.8) .541 15 (4.3) 44 (5.6) .312
 Cardiovascular diseases 4 (1.4) 39 (3.4) .082 3 (1.6) 30 (4.0) .125
 Asthma 20 (7.0) 16 (1.4) <.001 14 (7.4) 13 (1.7) <.001
 Atopic dermatitis 4 (1.4) 3 (0.3) .033 4 (2.1) 3 (0.4) .033
 Thyroid diseases 14 (4.9) 11 (1.0) <.001 11 (5.9) 9 (1.2) <.001
 Malignancy 5 (1.8) 19 (1.7) 1.000 3 (1.6) 16 (2.1) .780
 Mental disorders 6 (2.1) 19 (1.7) .615 4 (2.1) 18 (2.4) 1.000
History
 Allergic episodes for drugs 81 (28.5) 36 (3.2) <.001 54 (28.7) 28 (3.7) <.001
 Allergic episodes for foods 76 (26.8) 29 (2.6) <.001 49 (26.1) 20 (2.7) <.001
 Vasovagal episode 8 (2.8) 10 (0.9) .016 3 (1.6) 5 (0.7) .202
No. of vaccine doses received
 First 189 (66.5) 756 (66.5) 1.000 128 (68.1) 512 (68.1) 1.000
 Second 95 (33.5) 380 (33.5) 60 (31.9) 240 (31.9)
Period
 May 24-June 23 90 (31.7) 360 (31.7) 1.000 72 (38.3) 288 (38.3) 1.000
 June 24-July 23 57 (20.1) 228 (20.1) 30 (16.0) 120 (16.0)
 July 24-August 23 80 (28.2) 320 (28.2) 50 (26.6) 200 (26.6)
 August 24-September 24 57 (20.1) 228 (20.1) 36 (19.1) 144 (19.1)

Data are presented as n (%).

IHSR-2, Initial case definition without respiratory symptoms; IHSR-3, initial case definition included only clinical signs.